Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
26 September, 2017 00:20 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Gayatri Projects' JV bags order worth Rs 14.83 bn - 25-Sep-2017 15:15
Lupin receives USFDA approval for generic Clobex lotion - 25-Sep-2017 14:53
Suven Life Sciences secures product patents in India, Japan - 25-Sep-2017 12:10
Infosys' arm enters into partnership with ToneTag - 22-Sep-2017 15:25
REC gets nod to incorporate 5 project specific SPVs as WOS - 22-Sep-2017 11:51
KNR Constructions' JV bags order worth Rs 8.84 bn - 22-Sep-2017 10:09
Cox & Kings owned Meininger Hotels inks pact with Swiss developer - 22-Sep-2017 10:05
Cox & Kings owned Meininger Hotels inks pact with Swiss developer - 22-Sep-2017 10:05
Zydus Cadila gets USFDA nod for Itraconazole capsules - 22-Sep-2017 10:00
Unichem Lab receives ANDA approval for anti-hypertension drug - 21-Sep-2017 09:59
NBCC receives LoI worth Rs 32 bn from Dept of Customs & Excise - 21-Sep-2017 09:57
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer